Trial0

Clinical trial · NCT07628257 · NOT_YET_RECRUITING · NA

Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up

Sponsor: Centre Paul Strauss

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms. This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.

Interventions

  • 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences · OTHER

    fluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Adult patients
* Patients with glioblastoma
* Patients treated in the Nuclear Medicine \& Molecular Imaging Department of the Strauss Institute for PET/MRI scans for:

  * Preoperative metabolic evaluation of a brain-expanding lesion

Exclusion Criteria:

* Contraindications to MRI
* Minor or incapacitated adult
* Patient deprived of liberty
* Patient under legal guardianship
* Patient unable to consent
* Pregnant or breastfeeding woman

Sites (1)

  • Institut public de cancérologie Strauss Europe, Strasbourg, France

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-06-04.